Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) price on Thursday, July 03, fall -0.85% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.16.
A look at the stock’s price movement, the close in the last trading session was $1.17, moving within a range at $1.14 and $1.19. The beta value (5-Year monthly) was 0.208. Turning to its 52-week performance, $6.45 and $0.72 were the 52-week high and 52-week low respectively. Overall, BCLI moved 7.41% over the past month.
Brainstorm Cell Therapeutics, Inc’s market cap currently stands at around $11.41 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-15.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BCLI is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend BCLI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BCLI’s current price about -1.40% and -0.03% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.99, while 7-day volatility ratio is 6.92% and 7.79% in the 30-day chart. Further, Brainstorm Cell Therapeutics, Inc (BCLI) has a beta value of 0.13.
If we refocus on Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI), historical trading data shows that trading volumes averaged 0.37 over the past 10 days and 1.37 million over the past 3 months. The company’s latest data on shares outstanding shows there are 7.91 million shares.
The 22.32% of Brainstorm Cell Therapeutics, Inc’s shares are in the hands of company insiders while institutional holders own 10.40% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.46 million on 2025-06-13, giving us a short ratio of 0.15. The data shows that as of 2025-06-13 short interest in Brainstorm Cell Therapeutics, Inc (BCLI) stood at 645.0 of shares outstanding, with shares short rising to 0.21 million registered in 2025-05-15. Current price change has pushed the stock -78.34% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BCLI stock continues to rise going into the next quarter.
